Share This Article:

MicroRNAs as Targets and Tools in B-Cell Lymphoma Therapy

Abstract Full-Text HTML Download Download as PDF (Size:205KB) PP. 466-474
DOI: 10.4236/jct.2013.43A057    3,158 Downloads   4,988 Views   Citations

ABSTRACT

MicroRNAs (miRNAs) are posttranscriptional regulators fine-tuning the level of most messenger RNAs (mRNAs) and proteins in mammalian cells. Their expression is dysregulated in neoplastic cells and upregulated or downregulated miRNAs play an important role in tumorigenesis. Changes in the miRNA transcriptome appear to be suitable markers for the differential diagnosis of various B-cell lymphoma types and there are therapeutic attempts to normalize the expression level of key cellular miRNAs involved in lymphomagenesis. In this review we wish to outline the most recent developments in the application of sophisticated, chemically modified antisense oligonucleotides and their nanoparticle complexes to suppress oncogenic miRNAs. These advances form the basis of a new therapeutic approach that may complement current protocols for B-cell lymphoma therapy. Anti-cytokine therapy aiming at the removal of cytokines that activate key oncomirs, and switching on silenced tumor suppressor miRNAs by epigenetic drugs might also be considered, on the long run, in the treatment of well defined B-cell lymphoma types.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

K. Szenthe, K. Nagy, K. Buzas, H. Niller and J. Minarovits, "MicroRNAs as Targets and Tools in B-Cell Lymphoma Therapy," Journal of Cancer Therapy, Vol. 4 No. 3A, 2013, pp. 466-474. doi: 10.4236/jct.2013.43A057.

References

[1] D. Sayed and M. Abdellatif, “MicroRNAs in Development and Disease,” Physiological Reviews, Vol. 91, No. 3, 2011, pp. 827-887. doi:10.1152/physrev.00006.2010
[2] L. Ma and A. Weinberg, “MicroRNAs in Malignant Progression,” Cell Cycle, Vol. 7, No. 5, 2008, pp. 570-572. doi:10.4161/cc.7.5.5547
[3] S. A. Melo and M. Esteller, “Dysregulation of microRNAs in Cancer: Playing with Fire,” FEBS Letters, Vol. 585, No. 13, 2011, pp. 2087-2099. doi:10.1016/j.febslet.2010.08.009
[4] M. Fabbri and C. M. Croce, “Role of microRNAs in Lymphoid Biology and Disease,” Current Opinion in Hematology, Vol. 18, No. 4, 2011, pp. 266-272. doi:10.1097/MOH.0b013e3283476012
[5] L. Di Lisio, M. Sánchez-Beato, G. Gómez-López, M. E. Rodríguez, S. Montes-Moreno, M. Mollejo, J. Menárguez, M. A. Martínez, F. J. Alves, D. G. Pisano, M. A. Piris and N. Martínez, “MicroRNA Signatures in B-Cell Lymphomas,” Blood Cancer Journal, Vol. 2, No. 2, 2012, Article ID: e57. doi:10.1038/bcj.2012.1
[6] P. S. Eis, W. Tam, L. Sun, A. Chadbun, Z. Li, M. F. Gomez, E. Lund and J. E. Dahlberg, “Accumulation of miR-155 and BIC RNA in Human B Cell Lymphomas,” Proceedings of the National Academy of Sciences, USA, Vol. 102, No. 10, 2005, pp. 3627-3632. doi:10.1073/pnas.0500613102
[7] J. Kluiver, S. Poppema, D. de Jong, T. Blokzijl, G. Harms, S. Jacobs, B. J. Kroessen and A. van den Berg, “BIC and miR-155 Are Highly Expressed in Hodgkin, Primary Mediastinal and Diffuse Large B Cell Lymphomas,” Journal of Pathology, Vol. 207, No. 2, 2005, pp. 243-249. doi:10.1002/path.1825
[8] S. Costinean, N. Zanesi, Y. Pekarsky, E. Tili, S. Volinia, N. Heerema and C. M. Croce, “Pre-B Cell Proliferation and Lymphoblastic Leukemia/High-Grade Lymphoma in E(mu)-miR155 Transgenic Mice,” Proceedings of the National Academy of Sciences, USA, Vol. 103, No. 18, 2006, pp. 7024-7029. doi:10.1073/pnas.0602266103
[9] S. Costinean, S. K. Sandhu, I. M. Pedersen, E. Tili, R. Trotta, D. Perrotti, D. Ciarlariello, P. Neviani, J. Harb, L. R. Kauffmann, A. Shidham and C. M. Croce, “Src Homology Domain-Containing Inositol-5-Phosphatase and CCAAT Enhancer-Binding Protein β Are Targeted by miR-155 in B Cells of Eμ-MIR-155 Transgenic Mice,” Blood, Vol. 114, No. 7, 2009, pp. 1374-1382. doi:10.1182/blood-2009-05-220814
[10] C. L. Li, H. Nie, M. Wang, L. P. Su, J. F. Li, Y. Y. Yu, M. Yan, Q. L. Qu, Z. G. Zhu and B. Y. Liu, “microRNA-155 Is Downregulated in Gastric Cancer Cells and Involved in Cell Metastasis,” Oncology Report, Vo. 27, No. 6, 2012, pp. 1960-1966. doi:10.3892/or.2012.1719
[11] I. A. Babar, C. J. Cheng, C. J. Booth, X. Liang, J. B. Weidhaas, W. M. Saltzman and F. J. Slack, “Nanoparticle-based Therapy in an in Vivo microRNA-155 (miR-155)-Dependent Mouse Model of Lymphoma,” Proceedings of the National Academy of Sciences, USA, Vol. 109, No. 26, 2012, pp. E1695-E1704. doi:10.1073/pnas.1201516109
[12] A. G. Torres, M. M. Fabiani, E. Vigorito and M. J. Gait, “MicroRNA Fate upon Targeting with Anti-miRNA Oligonucleotides as Revealed by an Improved Northern-Blot-Based Method for miRNA Detection,” RNA-A Publication of RNA Society, Vol. 17, No. 5, 2011, pp. 933-943. doi:10.1261/rna.2533811
[13] O. Snove and J. J. Rossi, “Toxicity in Mice Expressing Short Hairpin RNAs Gives New Insight into RNAi,” Genome Biology, Vol. 7, No. 8, 2006, Article ID: 231. doi:10.1186/gb-2006-7-8-231
[14] D. Peer and M. Shimaoka, “Systemic siRNA Delivery to Leukocyte-Implicated Diseases,” Cell Cycle, Vol. 8, No. 6, 2009, pp. 853-859. doi:10.4161/cc.8.6.7936
[15] M. M. Fabani and M. J. Gait, “miR-122 Targeting with LNA/2’-O-Methyl Oligonucleotide Mixmers, Peptide Nucleic Acids (PNA), and PNA-Peptide Conjugates,” RNAA Publication of RNA Society, Vol. 14, No. 2, 2008, pp. 336-346. doi:10.1261/rna.844108
[16] M. M. Fabani, C. Abreu-Goodger, D. Williams, P. A. Lyons, A. G. Torres, K. G. C. Smith, A. J. Enright, M. J. Gait and E. Vigorito, “Efficient Inhibition of miR-155 Function in Vivo by Peptide Nucleic Acids,” Nucleic Acids Research, Vol. 38, No. 13, 2010, pp. 4466-4475. doi:10.1093/nar/gkq160
[17] J. Krützfeldt, S. Kuwajima, R. Braich, K. G. Rajeev, J. Pena, T. Tuschl, M. Manoharan and M. Stoffel, “Specificity, Duplex Degradation and Subcellular Localization of Antagomirs,” Nucleic Acids Research, Vol. 35, No. 9, 2007, pp. 2885-2892. doi:10.1093/nar/gkm024
[18] Y. Zhang, A. M. Roccaro, C. Rombaoa, L. Flores, S. Obad, S. M. Fernandes, A. Sacco, Y. Liu, H. Ngo, P. Quang, A. K. Azab, F. Azab, P. Maiso, M. Reagan, J. R. Brown, T. H. Thai, S. Kauppinen and I. M. Ghobrial, “LNA-Mediated Anti-miR-155-Silencing in Low Grade B-Cell Lymphomas,” Blood, Vol. 120, No. 8, 2012, pp. 1678-1686. doi:10.1182/blood-2012-02-410647
[19] V. Prabhu, S. Uzzaman, V. M. B. Grace and C. Guruvayoorappan, “Nanoparticles in Drug Delivery and Cancer Therapy: The Giant Rats Tail,” Journal of Cancer Therapy, Vol. 2, 2011, pp. 325-334. doi:10.4236/jct.2011.23045
[20] J. Su, H. Baigude, J. McCarroll and T. M. Rana, “Silencing microRNA by Interfering Nanoparticles in Mice,” Nucleic Acids Research, Vol. 39, No. 6, 2011, Article ID: e38. doi:10.1093/nar/gkq1307
[21] T. H. Thai, D. P. Calado, K. M. Ansel, C. Xiao, Y. Xue, A. Murphy, D. Frendewey, D. Valenzuela, J. L. Kutok, M. Schmidt-Supprian, N. Rajewsky, G. Yancopoulos, A. Rao and K. Rajewsky, “Regulation of the Germinal Center Response by microRNA-155,” Science, Vol. 316, No. 5824, 2007, pp. 604-608. doi:10.1126/science.1141229
[22] I. Pedersen, D. Otero, A. V. Miletic, C. Hother, E. Ralfkiaer, R. C. Rickert, K. Gronbaek and M. David, “OncomiR-155 Targets SHIP1 to Promote TNFα-Dependent Growth of B Cell Lymphomas,” EMBO Molecular Medicine, Vol. 1, No. 5, 2009, pp. 288-295. doi:10.1002/emmm.200900028
[23] Y. A. Mian and N. J. Zeleznik-Le, “MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets,” Current Drug Targets, Vol. 11, No. 7, 2010, pp. 801-811. doi:10.2174/138945010791320872
[24] V. J. Craig, S. B. Cogliatti, J. Imig, C. Renner, S. Neuenschwander, H. Rehrauer, R. Schlapbach, S. Dimhofer, A. Tzankov and A. Müller, “Myc-Mediated Repression of microRNA-34a Promotes High-Grade Transformation of B Cell Lymphoma by Dysregulation of FoxP1,” Blood, Vol. 117, No. 23, 2011, pp. 6227-6236.
[25] X. Zhang, X. Zhao, W. Fiskus, J. Lin, T. Lwin, R. Rao, Y. Zhang, J. C. Chan, K. Fu, V. E. Marquez, S. Chen-Kiang, L. C. Moscinski, E. Seto, W. S. Dalton, K. L. Wright, E. Sotomayor, K. Bhalla and J. Tao, “Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B Cell Lymphoma,” Cancer Cell, Vol. 22, No. 4, 2012, pp. 506-523. doi:10.1016/j.ccr.2012.09.003
[26] J. J. Zhao, J. Lin, T. Lwin, H. Yang, J. Guo, W. Kong, S. Dessureault, L. C. Moscinski, D. Rezania, W. S. Dalton, E. Sotomayor, J. Tao and J. Q. Cheng, “microRNA Expression Profile and Identification of miR-29 as a Prognostic Marker and Pathogenic Factor by Targeting CDK6 in Mantle Cell Lymphoma,” Blood, Vol. 115, No. 13, 2010, pp. 2630-2639. doi:10.1182/blood-2009-09-243147
[27] M. Takacs, F. Banati, A. Koroknai, J. Segesdi, D. Salamon, H. Wolf, H. H. Niller and J. Minarovits, “Epigenetic Regulation of Latent Epstein-Barr Virus Promoters,” Biochimica et Biophysica Acta, Vol. 1799, No. 3-4, 2010, pp. 228-235. doi:10.1016/j.bbagrm.2009.10.005
[28] J. E. Cameron, Q. Yin, C. Fewell, M. Lacey, J. McBride, X. Wang, Z. Lin, B. C. Schaefer and E. K. Flemington, “Epstein-Barr Virus Latent Membrane Protein 1 Induces Cellular microRNA miR-146A, a Modulator of Lymphocyte Signaling Pathways,” Journal of Virology, Vol. 82, No. 4, 2008, pp. 1946-1958. doi:10.1128/JVI.02136-07
[29] F. Lu, A. Weidmer, C. G. Liu, S. Volnia, C. M. Croce and P. M. Lieberman, “Epstein-Barr Virus-Induced miR-155 Attenuates NF-kappaB Signaling and Stabilizes Latent Virus Persistence,” Journal of Virology, Vol. 82, No. 21, 2008, pp. 10436-10443. doi:10.1128/JVI.00752-08
[30] B. R. Cullen, “Viruses and microRNAs: RISCy Interactions with Serious Consequences,” Genes & Development, Vol. 25, No. 18, 2011, pp. 1881-1894.
[31] A. P. Skarbnik and M. R. Smith, “Radioimmunotherapy in Mantle Cell Lymphoma,” Best Practice & Research Clinical Haematology, Vol. 25, No. 2, 2012, pp. 201-210. doi:10.1016/j.beha.2012.04.004
[32] P. Jiang, E. Y. Rao, N. Meng, Y. Zhao and J. J. Wang, “MicroRNA-17-92 Significantly Enhances Radioresistance in Human Mantle Cell Lymphoma Cells,” Radiation Oncology, Vol. 5, 2010, Article ID: 100. doi:10.1186/1748-717X-5-100
[33] I. A. Babar, J. Czochor, A. Steinmetz, J. B. Weidhaas, P. M. Glazer and F. J. Slack, “Inhibition of Hypoxia-Induced miR-155 Radiosensitizes Hypoxic Lung Cancer Cells,” Cancer Biology & Therapy, Vol. 12, No. 10, 2012, pp. 908-914. doi:10.4161/cbt.12.10.17681
[34] E. Rao, C. Jiang, M. Ji, X. Huang, J. Ibgal, G. Lenz, G. Wright, L. M. Staudt, Y. Zhao, T. W. McKeithan, W. C. Chan and K. Fu, “The miRNA-17~92 Cluster Mediates Chemoresistance and Enhances Tumor Growth in Mantle Cell Lymphoma via PI3K/AKT Pathway Activation,” Leukemia, Vol. 26, No. 5, 2012, pp. 1064-1072. doi:10.1038/leu.2011.305
[35] J. H. Gibcus, L. P. Tan, G. Harms, R. N. Schakel, D. de Jong, T. Blokzijl, P. M?ller, S. Poppema, B. J. Kroesen and A. van den Berg, “Hodgkin Lymphoma Cell Lines Are Characterized by a Specific miRNA Expression Profile,” Neoplasia, Vol. 11, No. 2, 2009, pp. 167-176.
[36] A. Roehle, K. P. Hoefig, D. Repsilber, C. Thorns, M. Ziepert, K. O. Wesche, M. Thiere, M. Loeffler, W. Klapper, M. Pfreundschuh, A. Matolcsy, H. W. Bernd, L. Reiniger, H. Merz and A. C. Feller, “MicroRNA Signatures Characterize Diffuse Large B-Cell Lymphomas and Follicular Lymphomas,” British Journal of Haematology, Vol. 142, No. 5, 2008, pp. 732-744. doi:10.1111/j.1365-2141.2008.07237.x
[37] C. H. Lawrie, J. Chi, S. Taylor, D. Tramonti, E. Ballabio, S. Palazzo, N. J. Saunders, F. Pezzella, J. Boultwood, J. S. Wainscoat and C. S. Hatton, “Expression of microRNAs in Diffuse Large B Cell Lymphoma Is Associated with Immunophenotype, Survival and Transformation from Follicular Lymphoma,” Journal of Cellular and Molecular Medicine, Vol. 13, No. 7, 2009, pp. 1248-1260. doi:10.1111/j.1582-4934.2008.00628.x
[38] D. Rai, S. Karanti, I. Jung, P. L. Dahia and R. C. Aguiar, “Coordinated Expression of microRNA-155 and Predicted Target Genes in Diffuse Large B-Cell Lymphoma,” Cancer Genetics and Cytogenetics, Vol. 181, No. 1, 2008, pp. 8-15. doi:10.1016/j.cancergencyto.2007.10.008
[39] S. Y. Park, J. H. Lee, M. Ha, J. W. Nam and V. N. Kim, “miR-29 miRNAs Activate p53 by Targeting p85 Alpha and CDC42,” Nature Structural and Molecular Biology, Vol. 16, No. 1, 2009, pp. 23-29. doi:10.1038/nsmb.1533
[40] L. Fischer, M. Hummel, A. Korfel, D. Lenze, K. Joehrens and E. Thiel, “Differential micro-RNA Expression in Primary CNS and Nodal Diffuse Large B-Cell Lymphomas,” Neuro-Oncology, Vol. 13, No. 10, 2011, pp. 1090-1098. doi:10.1093/neuonc/nor107
[41] L. Du, J. J. Schageman, M. C. Subauste, B. Saber, S. M. Hammond and L. Prudkin, “miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1,” Molecular Cancer Research, Vol. 7, No. 8, 2009, pp. 1234-1243. doi:10.1158/1541-7786.MCR-08-0507
[42] C. Xiao, D. P. Calado, G. Galler, T. H. Thai, H. C. Patterson, J. Wang, N. Rajewsky, T. P. Bender and K. Rajewsky, “MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb,” Cell, Vol. 131, No. 1, 2007, pp. 146-159. doi:10.1016/j.cell.2007.07.021
[43] A. J. Arribas, Y. Campos-Martín, C. Gómez-Abad, P. Algara, M. Sánchez-Beato, M. S. Rodriguez-Pinilla, S. Montes-Moreno, N. Martinez, J. Alves-Ferreira, M. A. Piris and M. Mollejo, “Nodal Marginal Zone Lymphoma: Gene Expression and miRNA Profiling Identify Diagnostic Markers and Potential Therapeutic Targets,” Blood, Vol. 119, No. 3, 2012, pp. e9-e21. doi:10.1182/blood-2011-02-339556
[44] S. M. Park, A. B. Gaur, E. Lengyel and M. E. Peter, “The miR-200 Family Determines the Epithelial Phenotype of Cancer Cells by Targeting the E-Cadherin Repressors ZEB1 and ZEB2,” Genes Development, Vol. 22, No. 7, 2008, pp. 894-907. doi:10.1101/gad.1640608
[45] L. Di Lisio, G. Gomez-Lopez, M. Sanchez-Beato, C. Gomez-Abad, M. E. Rodriguez, R. Villuendas, B. I. Ferreira, A. Carro, D. Rico, M. Mollejo, M. A. Martínez, J. Menárguez, A. Díaz-Alderete, J. Gil, J. C. Cigudosa, D. G. Pisano, M. A. Piris and N. Martínez, “Mantle Cell Lymphoma: Transcriptional Regulation by microRNAs,” Leukemia, Vol. 24, No. 7, 2010, pp. 1335-1342. doi:10.1038/leu.2010.91
[46] A. Onnis, G. de Falco, G. Antonicelli, M. Onorati, C. Bellan, O. Sherman, S. Sayed and L. Leoncini, “Alteration of microRNAs Regulated by c-Myc in Burkitt Lymphoma,” PLoS ONE, Vol. 5, No. 9, 2010, p. e12960. doi:10.1371/journal.pone.0012960
[47] L. S. Hodge, S. F. Elsawa, D. M. Grote, T. L. Price-Troska, Y. W. Asmann, R. Fonseca, M. A. Gertz, T. E. Witzig, A. J. Novak and S. M. Ansell, “MicroRNA Expression in Tumor Cells from Waldenstrom’s Macroglobulinemia Reflects Both Their Normal and Malignant Cell Counterparts,” Blood Cancer Journal, Vol. 1, No. 6, 2011, Article ID: e24. doi:10.1038/bcj.2011.25
[48] E. Braggio, C. Philipsborn, A. Novak, L. Hodge, S. Ansell and R. Fonseca, “Molecular Pathogenesis of Waldenstrom’s Macroglobulinemia,” Haematologica, Vol. 97, No. 9, 2012, pp. 1281-1290. doi:10.3324/haematol.2012.068478
[49] A. M. Roccaro, A. Sacco, C. Chen, J. Runnels, X. Leleu, F. Azab, A. K. Azab, X. Jia, H. T. Ngo, M. R. Melhem, N. Burwick, L. Varticovski, C. D. Novina, B. J. Rollins, K. C. Anderson and I. M. Ghobrial, “MicroRNA Expression in the Biology, Prognosis, and Therapy of Waldenstr?m Macroglobulinemia,” Blood, Vol. 113, No. 18, 2009, pp. 4391-4402. doi:10.1182/blood-2008-09-178228
[50] Z. Li, J. Lu, M. Sun, S. Mi, H. Zhang, R. T. Luo, P. Chen, Y. Wang, M. Yan, Z. Qian, M. B. Neilly, J. Jin, Y. Zhang, S. K. Bohlander, D. E. Zhang, R. A. Larson, M. M. Le Beau, M. J. Thirman, T. R. Golub, J. D. Rowley and J. Chen, “Distinct microRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 40, 2008, pp. 15535-15540. doi:10.1073/pnas.0808266105
[51] G. A. Calin, C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler, S. Rattan, M. Keating K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich and C. M. Croce, “Frequent Deletions and Down-Regulation of Micro-RNA Genes miR15 and miR16 at 13q14 in Chronic Lymphocytic Leukemia,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, No. 24, 2002, pp. 15524-15529. doi:10.1073/pnas.242606799
[52] F. Haller, A. Von Heydebreck, J. D. Zhang, B. Gunawan, C. Langer, G. Ramadori, S. Wiemann and O. Sahin, “Localization- and Mutation-Dependent microRNA (miRNA) Expression Signatures in Gastrointestinal Stromal Tumours (GISTs), with a Cluster of Co-Expressed miRNAs Located at 14q32.31,” Journal of Pathology and Bacteriology, Vol. 220, No. 1, 2010, pp. 71-86. doi:10.1002/path.2610
[53] J. L. Robertus, J. Kluiver, C. Weggemans, G. Harms, R. M. Reijmers, Y. Swart, K. Kok, S. Rosati, E. Schuuring, G. van Imhoff, S. T. Pals, P. Kluin and A. van den Berg, “MiRNA Profiling in B Non-Hodgkin Lymphoma: A MYC-Related miRNA Profile Characterizes Burkitt Lymphoma,” British Journal of Haematology, Vol. 149, No. 6, 2010, pp. 896-899. doi:10.1111/j.1365-2141.2010.08111.x

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.